Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Acquisitions & Divestments: 2016-2025

Historic Change in Acquisitions & Divestments for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Sep 2025 value amounting to $123.0 million.

  • Rocket Pharmaceuticals' Change in Acquisitions & Divestments rose 23.21% to $123.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.2 million, marking a year-over-year increase of 1.88%. This contributed to the annual value of $383.5 million for FY2024, which is 23.96% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Change in Acquisitions & Divestments stood at $123.0 million, which was up 45.56% from $84.5 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Change in Acquisitions & Divestments peaked at $123.0 million during Q3 2025, and registered a low of $38.3 million during Q4 2021.
  • Its 3-year average for Change in Acquisitions & Divestments is $89.3 million, with a median of $86.5 million in 2024.
  • In the last 5 years, Rocket Pharmaceuticals' Change in Acquisitions & Divestments skyrocketed by 247.87% in 2021 and then fell by 23.97% in 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Change in Acquisitions & Divestments (Quarterly) stood at $38.3 million in 2021, then skyrocketed by 32.70% to $50.8 million in 2022, then spiked by 42.35% to $72.3 million in 2023, then climbed by 19.54% to $86.5 million in 2024, then climbed by 23.21% to $123.0 million in 2025.
  • Its last three reported values are $123.0 million in Q3 2025, $84.5 million for Q2 2025, and $82.3 million during Q1 2025.